- Home
- EDUC vs NERV Comparison
EDUC vs NERV Comparison
Compare EDUC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDUC
- NERV
- Stock Information
- Founded
- EDUC 1965
- NERV 2007
- Country
- EDUC United States
- NERV United States
- Employees
- EDUC N/A
- NERV N/A
- Industry
- EDUC Consumer Specialties
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- EDUC Consumer Discretionary
- NERV Health Care
- Exchange
- EDUC Nasdaq
- NERV Nasdaq
- Market Cap
- EDUC 11.4M
- NERV 12.0M
- IPO Year
- EDUC N/A
- NERV 2014
- Fundamental
- Price
- EDUC $1.11
- NERV $2.34
- Analyst Decision
- EDUC
- NERV Hold
- Analyst Count
- EDUC 0
- NERV 1
- Target Price
- EDUC N/A
- NERV $5.00
- AVG Volume (30 Days)
- EDUC 313.8K
- NERV 41.3K
- Earning Date
- EDUC 10-09-2025
- NERV 11-04-2025
- Dividend Yield
- EDUC N/A
- NERV N/A
- EPS Growth
- EDUC N/A
- NERV N/A
- EPS
- EDUC N/A
- NERV 1.48
- Revenue
- EDUC $31,304,000.00
- NERV N/A
- Revenue This Year
- EDUC N/A
- NERV N/A
- Revenue Next Year
- EDUC N/A
- NERV N/A
- P/E Ratio
- EDUC N/A
- NERV $1.62
- Revenue Growth
- EDUC N/A
- NERV N/A
- 52 Week Low
- EDUC $0.92
- NERV $1.15
- 52 Week High
- EDUC $2.49
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- EDUC 42.35
- NERV 59.24
- Support Level
- EDUC $1.08
- NERV $2.26
- Resistance Level
- EDUC $1.18
- NERV $2.47
- Average True Range (ATR)
- EDUC 0.08
- NERV 0.17
- MACD
- EDUC 0.01
- NERV -0.00
- Stochastic Oscillator
- EDUC 31.25
- NERV 64.19
About EDUC Educational Development Corporation
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.